GSK - Agenus At The Time Of The Coronavirus

Intro & pipeline

Agenus (AGEN) is an immuno-oncology ((IO)) company with a deep and diversified pipeline, a technology for novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing. Agenus believes that these fully integrated capabilities are the best way to produce novel candidates on timelines that are shorter than the industry standard.

Its most advanced antibody candidates are balstilimab (anti-PD1) and zalifrelimab (anti-CTLA4), which are currently in Phase 2 trials of balstilimab monotherapy and balstilimab/zalifrelimab combination for patients with second-line cervical cancer. Both of these trials will potentially